董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ketan Seth | 男 | Chief Executive Officer and Director | 50 | 未披露 | 716.09 | 2026-02-19 |
| David Bauer | 男 | Chief Financial Officer and Director | 42 | 未披露 | 未持股 | 2026-02-19 |
| Wesley Clark | 男 | Non-Executive Chairman of the Board | 81 | 未披露 | 未持股 | 2026-02-19 |
| Kenneth Moritsugu | 男 | Director | 80 | 未披露 | 未持股 | 2026-02-19 |
| Nadim Qureshi | 男 | Director | 51 | 未披露 | 未持股 | 2026-02-19 |
| Dario Dino Ferrari | 男 | Director | 57 | 未披露 | 未持股 | 2026-02-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ketan Seth | 男 | Chief Executive Officer and Director | 50 | 未披露 | 716.09 | 2026-02-19 |
| David Bauer | 男 | Chief Financial Officer and Director | 42 | 未披露 | 未持股 | 2026-02-19 |
董事简历
中英对照 | 中文 | 英文- Ketan Seth
-
Ketan Seth，自2025年2月10日起担任公司董事，自2025年2月10日起担任首席执行官，在科技领域以及数据中心领域拥有20年的交易经验。自2022年10月以来，Seth先生一直担任Vezbi的首席执行官，Vezbi是美国首家专注于为美国以及拉丁美洲的B2B客户提供远程医疗以及小额支付和汇款系统等医疗保健服务的超级应用程序。此外，自2020年8月以来，Seth先生一直担任AT Health Inc.（前身为Innovative Health Consulting LLC）的首席执行官，自2011年1月以来，Seth先生一直担任Alpha Trading LLC的管理合伙人，该公司是一家总部位于美国的私人投资控股公司，专注于金融科技和医疗保健。2005年至2012年，Seth先生担任创新物流解决方案的首席执行官。2000年至2004年，Seth先生在德意志银行投资银行部门工作，协助处理交易流程和私募发行。1998年至2000年，Seth先生在德勤咨询公司担任业务战略顾问。塞思先生在密歇根大学获得经济学学士学位，在纽约大学斯特恩商学院获得MBA学位，在那里他专注于金融、创业和战略。
Ketan Seth a director since February 10, 2025 and Chief Executive Officer since February 10, 2025, has 20 years of deal making experience in the tech sector as ll as in the data centers space. Since October 2022, Mr. Seth has been the Chief Executive Officer of Vezbi, the first American Super App focused on healthcare services such as telemedicine and small payment and remittance systems for B2B clients both in the as ll as LatAm. In addition, since August 2020, Mr. Seth has been Chief Executive Officer of AT Health Inc. (formerly Innovative Health Consulting LLC) and since January 2011, Mr. Seth has been managing partner of Alpha Trading LLC, a based private investment holding company focused on fintech and healthcare. From 2005 to 2012, Mr. Seth was Chief Executive Officer of Innovative Logistics Solutions. From 2000 to 2004, Mr. Seth worked in the Deutsche Bank Investment Banking division, assisting on deal flow and private placements. From 1998 to 2000, Mr. Seth served as a Biness Strategy Consultant at Deloitte Consulting. Mr. Seth earned a BA in Economics from University of Michigan and an MBA from the Stern School of Biness at NYU, where he focused in Finance, Entrepreneurship and Strategy. - Ketan Seth，自2025年2月10日起担任公司董事，自2025年2月10日起担任首席执行官，在科技领域以及数据中心领域拥有20年的交易经验。自2022年10月以来，Seth先生一直担任Vezbi的首席执行官，Vezbi是美国首家专注于为美国以及拉丁美洲的B2B客户提供远程医疗以及小额支付和汇款系统等医疗保健服务的超级应用程序。此外，自2020年8月以来，Seth先生一直担任AT Health Inc.（前身为Innovative Health Consulting LLC）的首席执行官，自2011年1月以来，Seth先生一直担任Alpha Trading LLC的管理合伙人，该公司是一家总部位于美国的私人投资控股公司，专注于金融科技和医疗保健。2005年至2012年，Seth先生担任创新物流解决方案的首席执行官。2000年至2004年，Seth先生在德意志银行投资银行部门工作，协助处理交易流程和私募发行。1998年至2000年，Seth先生在德勤咨询公司担任业务战略顾问。塞思先生在密歇根大学获得经济学学士学位，在纽约大学斯特恩商学院获得MBA学位，在那里他专注于金融、创业和战略。
- Ketan Seth a director since February 10, 2025 and Chief Executive Officer since February 10, 2025, has 20 years of deal making experience in the tech sector as ll as in the data centers space. Since October 2022, Mr. Seth has been the Chief Executive Officer of Vezbi, the first American Super App focused on healthcare services such as telemedicine and small payment and remittance systems for B2B clients both in the as ll as LatAm. In addition, since August 2020, Mr. Seth has been Chief Executive Officer of AT Health Inc. (formerly Innovative Health Consulting LLC) and since January 2011, Mr. Seth has been managing partner of Alpha Trading LLC, a based private investment holding company focused on fintech and healthcare. From 2005 to 2012, Mr. Seth was Chief Executive Officer of Innovative Logistics Solutions. From 2000 to 2004, Mr. Seth worked in the Deutsche Bank Investment Banking division, assisting on deal flow and private placements. From 1998 to 2000, Mr. Seth served as a Biness Strategy Consultant at Deloitte Consulting. Mr. Seth earned a BA in Economics from University of Michigan and an MBA from the Stern School of Biness at NYU, where he focused in Finance, Entrepreneurship and Strategy.
- David Bauer
-
David Bauer，自2025年2月25日起担任首席财务官并担任董事，在2015年至2025年1月期间，他担任数字媒体物业和管理公司Matters Media（现为Engrost Inc.）的首席执行官兼董事，在那里他领导了该控股公司的所有运营和并购活动，包括金融业务。2012年至2015年，Bauer先生担任Zenia集团金融服务领域的运营、并购咨询主管。2007年至2010年，Bauer先生受雇于高盛 Sachs，担任不良贷款和票面贷款的管理、交易和服务方面的金融分析师，并且是合成银行贷款团队的负责人。
David Bauer Chief Financial Officer since February 25, 2025 and a director since June 12, 2025, served as CEO and a director of Matters Media (now Engrost Inc.), a digital media properties and management firm, from 2015 to January 2025, where he led all operations and M&A activity for the holding company, including financial operations. From 2012 to 2015, Mr. Bauer was head of operations, M&A Advisory in the financial services sector for Zenia Group. From 2007 to 2010, Mr. Bauer was employed by Goldman Sachs as a Financial Analyst in management, trading and servicing of distressed and par loans and was leader of the synthetic bank loans team. - David Bauer，自2025年2月25日起担任首席财务官并担任董事，在2015年至2025年1月期间，他担任数字媒体物业和管理公司Matters Media（现为Engrost Inc.）的首席执行官兼董事，在那里他领导了该控股公司的所有运营和并购活动，包括金融业务。2012年至2015年，Bauer先生担任Zenia集团金融服务领域的运营、并购咨询主管。2007年至2010年，Bauer先生受雇于高盛 Sachs，担任不良贷款和票面贷款的管理、交易和服务方面的金融分析师，并且是合成银行贷款团队的负责人。
- David Bauer Chief Financial Officer since February 25, 2025 and a director since June 12, 2025, served as CEO and a director of Matters Media (now Engrost Inc.), a digital media properties and management firm, from 2015 to January 2025, where he led all operations and M&A activity for the holding company, including financial operations. From 2012 to 2015, Mr. Bauer was head of operations, M&A Advisory in the financial services sector for Zenia Group. From 2007 to 2010, Mr. Bauer was employed by Goldman Sachs as a Financial Analyst in management, trading and servicing of distressed and par loans and was leader of the synthetic bank loans team.
- Wesley Clark
-
Wesley Clark，自2021年3月起担任ImmunityBio公司董事会成员。他于2021年2月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。他在美国陆军服役了34年，在1996年通过晋升获得了他作为正式将领的第四颗星。他曾于1997年至2000年担任北约欧洲最高盟军指挥官，在科索沃战争中指挥盟军行动。克拉克将军在其整个职业生涯中都获得了极高的勋章，他被美国总统William J. Clinton授予美国总统自由勋章。自2003年起，他担任Wesley K. Clark & Associates，LLC的董事长兼首席执行官，该公司是一家专注于业务发展、危机支持和战略传播的战略咨询公司。自2010年起，他担任精品投资银行Enverra，Inc.的董事长兼首席执行官。他目前自2022年8月起担任Directa Plus S.P.A.董事会成员，自2022年12月起担任MCF Energy Ltd.董事会成员。Gen. Clark此前曾于2020年至2023年在Equinox Gold Corp.以及2010年至2018年在Rentech，Inc.的董事会任职。他毕业于美国西点军校，在那里他是班级告别演说者。从西点军校毕业后，他获得了牛津大学的罗德奖学金，在那里他获得了哲学、政治和经济学学位。曾获指挥总参高等专科学校军事学硕士学位。
Wesley Clark a director since June 12, 2025, has served as a member of the Board of Directors of ImmunityBio, Inc. (NASDAQ: IBRX) since March 2021. Since 2003, he has served as chairman and chief executive officer of sley K. Clark & Associates, LLC, a strategic consulting firm specializing in biness development, crisis support and strategic communications. Since 2010, he has served as chairman and chief executive officer of Enverra, Inc., a boutique investment bank. General Clark has been a director of special purpose companies from December 14, 2021 to December 13, 2024, General Clark served as a director of Swiftmerge Acquisition Corp., and from September 2005 to October 2009, General Clark was a director of Argyle Security, Inc., formerly Argyle Security Acquisition Corporation. See "Prior SPAC Experience." He served for 34 years in the U.S. Army, rising through the ranks to earn his fth star as a full general in 1996. He served as the Supreme Allied Commander Europe of NATO from 1997 to 2000, where he commanded Operation Allied Force in the Kosovo War. Highly decorated throughout his career, Gen. Clark was awarded the U.S. Presidential Medal of Freedom by President William J. Clinton. He has been a director of Directa Pl S.p.A. since Augt 2022 and MCF Energy Ltd. since December 2022. Gen. Clark previoly served on the boards of directors of Equinox Gold Corp. from 2020 to 2023, and Rentech, Inc. from 2010 to 2018. He is a graduate of the U.S. Military Academy at st Point, where he was class valedictorian. After graduating from st Point, he was awarded a Rhodes Scholarship to the University of Oxford where he earned degrees in philosophy, politics and economics. He earned a master's degree in military science from the Command and General Staff College. - Wesley Clark，自2021年3月起担任ImmunityBio公司董事会成员。他于2021年2月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。他在美国陆军服役了34年，在1996年通过晋升获得了他作为正式将领的第四颗星。他曾于1997年至2000年担任北约欧洲最高盟军指挥官，在科索沃战争中指挥盟军行动。克拉克将军在其整个职业生涯中都获得了极高的勋章，他被美国总统William J. Clinton授予美国总统自由勋章。自2003年起，他担任Wesley K. Clark & Associates，LLC的董事长兼首席执行官，该公司是一家专注于业务发展、危机支持和战略传播的战略咨询公司。自2010年起，他担任精品投资银行Enverra，Inc.的董事长兼首席执行官。他目前自2022年8月起担任Directa Plus S.P.A.董事会成员，自2022年12月起担任MCF Energy Ltd.董事会成员。Gen. Clark此前曾于2020年至2023年在Equinox Gold Corp.以及2010年至2018年在Rentech，Inc.的董事会任职。他毕业于美国西点军校，在那里他是班级告别演说者。从西点军校毕业后，他获得了牛津大学的罗德奖学金，在那里他获得了哲学、政治和经济学学位。曾获指挥总参高等专科学校军事学硕士学位。
- Wesley Clark a director since June 12, 2025, has served as a member of the Board of Directors of ImmunityBio, Inc. (NASDAQ: IBRX) since March 2021. Since 2003, he has served as chairman and chief executive officer of sley K. Clark & Associates, LLC, a strategic consulting firm specializing in biness development, crisis support and strategic communications. Since 2010, he has served as chairman and chief executive officer of Enverra, Inc., a boutique investment bank. General Clark has been a director of special purpose companies from December 14, 2021 to December 13, 2024, General Clark served as a director of Swiftmerge Acquisition Corp., and from September 2005 to October 2009, General Clark was a director of Argyle Security, Inc., formerly Argyle Security Acquisition Corporation. See "Prior SPAC Experience." He served for 34 years in the U.S. Army, rising through the ranks to earn his fth star as a full general in 1996. He served as the Supreme Allied Commander Europe of NATO from 1997 to 2000, where he commanded Operation Allied Force in the Kosovo War. Highly decorated throughout his career, Gen. Clark was awarded the U.S. Presidential Medal of Freedom by President William J. Clinton. He has been a director of Directa Pl S.p.A. since Augt 2022 and MCF Energy Ltd. since December 2022. Gen. Clark previoly served on the boards of directors of Equinox Gold Corp. from 2020 to 2023, and Rentech, Inc. from 2010 to 2018. He is a graduate of the U.S. Military Academy at st Point, where he was class valedictorian. After graduating from st Point, he was awarded a Rhodes Scholarship to the University of Oxford where he earned degrees in philosophy, politics and economics. He earned a master's degree in military science from the Command and General Staff College.
- Kenneth Moritsugu
-
自2007年以来，Kenneth Moritsugu一直担任First Samurai Consulting，LLC的总裁兼首席执行官，该公司是一家专注于公共卫生系统和政策的健康咨询公司。森津谷少将于2002年担任美国代理外科医生，2006年7月至2007年再次担任代理外科医生，当时他从美国公共卫生服务（USPHS）委托军团退役。森津谷少将曾在USPHS担任职业军官37年，从1998年起担任美国副外科医生。他还曾担任以下关键的HHS和政府职位--医学司司长、卫生专业局副局长、National Health服务团团长，以及负责卫生服务的助理局局长和联邦监狱局医疗局长。从2007年起，Moritsugu博士担任强生糖尿病解决方案公司全球专业教育和战略关系副总裁，并曾担任强生（JJDI）全球主席，直到2013年从强生退休。他曾于2019年8月至2020年6月担任美国糖尿病协会临时首席科学和医疗官。Moritsugu博士就读于檀香山Chaminade学院，并获得夏威夷大学的荣誉学士学位和加州大学伯克利分校的健康管理和规划公共卫生硕士学位。Moritsugu博士在预防医学方面获得委员会认证；在美国预防医学学院、皇家公共卫生学会、皇家医学学会和国家公共行政学院拥有研究金；并且是一名经过认证的惩教健康专业人员。他是乔治华盛顿公共卫生大学全球健康兼职教授和统一服务大学Health Sciences预防医学兼职副教授。
Kenneth Moritsugu director since June 12, 2025, has been the President and Chief Executive Officer of First Samurai Consulting, LLC, a firm specializing in health consulting foced on public health systems and policies, since 2007. Rear Admiral Moritsugu was the Acting Surgeon General of the United States in 2002 and again from July 2006 to 2007, when he retired from the Commissioned Corps of the United States Public Health Service (PHS). Rear Admiral Moritsugu was a career officer in the PHS for 37 years, where he served as the Deputy Surgeon General of the United States from 1998. He also served in the following key HHS and government positions Director of the Division of Medicine, Deputy Director of the Bureau of Health Professions, Director of the National Health Service Corps, and Assistant Bureau Director for Health Services and Medical Director of the Federal Bureau of Prisons. From 2007, Dr. Moritsugu was the Vice President for Global Professional Education and Strategic Relations for Johnson & Johnson's Diabetes Solutions Companies, and former Worldwide Chairman of the Johnson & Johnson (JJDI), until his retirement from Johnson & Johnson in 2013. He served as the Interim Chief Science and Medical Officer of the American Diabetes Association from August 2019 through June 2020. Dr. Moritsugu attended Chaminade College of Honolulu and earned a baccalaureate Degree with Honors from the University of Hawaii and a Master of Public Health in Health Administration and Planning from the University of California, Berkeley. Dr. Moritsugu is Board certified in Preventive Medicine; holds Fellowships in the American College of Preventive Medicine, the Royal Society of Public Health, the Royalty Society of Medicine, and the National Academy of Public Administration; and is a Certified Correctional Health Professional. He is an Adjunct Professor of Global Health at the George Washington University of Public Health and Adjunct Associate Professor of Preventive Medicine at the Uniformed Services University of the Health Sciences. - 自2007年以来，Kenneth Moritsugu一直担任First Samurai Consulting，LLC的总裁兼首席执行官，该公司是一家专注于公共卫生系统和政策的健康咨询公司。森津谷少将于2002年担任美国代理外科医生，2006年7月至2007年再次担任代理外科医生，当时他从美国公共卫生服务（USPHS）委托军团退役。森津谷少将曾在USPHS担任职业军官37年，从1998年起担任美国副外科医生。他还曾担任以下关键的HHS和政府职位--医学司司长、卫生专业局副局长、National Health服务团团长，以及负责卫生服务的助理局局长和联邦监狱局医疗局长。从2007年起，Moritsugu博士担任强生糖尿病解决方案公司全球专业教育和战略关系副总裁，并曾担任强生（JJDI）全球主席，直到2013年从强生退休。他曾于2019年8月至2020年6月担任美国糖尿病协会临时首席科学和医疗官。Moritsugu博士就读于檀香山Chaminade学院，并获得夏威夷大学的荣誉学士学位和加州大学伯克利分校的健康管理和规划公共卫生硕士学位。Moritsugu博士在预防医学方面获得委员会认证；在美国预防医学学院、皇家公共卫生学会、皇家医学学会和国家公共行政学院拥有研究金；并且是一名经过认证的惩教健康专业人员。他是乔治华盛顿公共卫生大学全球健康兼职教授和统一服务大学Health Sciences预防医学兼职副教授。
- Kenneth Moritsugu director since June 12, 2025, has been the President and Chief Executive Officer of First Samurai Consulting, LLC, a firm specializing in health consulting foced on public health systems and policies, since 2007. Rear Admiral Moritsugu was the Acting Surgeon General of the United States in 2002 and again from July 2006 to 2007, when he retired from the Commissioned Corps of the United States Public Health Service (PHS). Rear Admiral Moritsugu was a career officer in the PHS for 37 years, where he served as the Deputy Surgeon General of the United States from 1998. He also served in the following key HHS and government positions Director of the Division of Medicine, Deputy Director of the Bureau of Health Professions, Director of the National Health Service Corps, and Assistant Bureau Director for Health Services and Medical Director of the Federal Bureau of Prisons. From 2007, Dr. Moritsugu was the Vice President for Global Professional Education and Strategic Relations for Johnson & Johnson's Diabetes Solutions Companies, and former Worldwide Chairman of the Johnson & Johnson (JJDI), until his retirement from Johnson & Johnson in 2013. He served as the Interim Chief Science and Medical Officer of the American Diabetes Association from August 2019 through June 2020. Dr. Moritsugu attended Chaminade College of Honolulu and earned a baccalaureate Degree with Honors from the University of Hawaii and a Master of Public Health in Health Administration and Planning from the University of California, Berkeley. Dr. Moritsugu is Board certified in Preventive Medicine; holds Fellowships in the American College of Preventive Medicine, the Royal Society of Public Health, the Royalty Society of Medicine, and the National Academy of Public Administration; and is a Certified Correctional Health Professional. He is an Adjunct Professor of Global Health at the George Washington University of Public Health and Adjunct Associate Professor of Preventive Medicine at the Uniformed Services University of the Health Sciences.
- Nadim Qureshi
-
Nadim Qureshi是BPGC Management LP的管理合伙人，该公司是一家专注于与全球工业、材料和化学品领域交易的全球私募股权公司，他于2020年与他人共同创立了该公司，负责公司和投资管理的各个方面。Qureshi先生自2021年1月起担任特殊目的收购公司BPGC Acquisition Corp.（原名Ross Acquisition Corp II，或“RAC II”）的并购主管，直至2024年底被任命为首席执行官。2021年3月16日，RAC II完成了34,500，000台的首次公开发行，总收益为345,000，000美元。RAC II的单位（以及单位中包含的A类普通股和认股权证）在纽约证券交易所（“NYSE”）上市，直到2024年4月3日，由于未能在其初始业务合并后的三年内完成初始业务合并而被摘牌。2024年9月16日，RAC将完成初步业务合并的期限延长至2026年3月16日。RAC II尚未完成其初始业务合并，目前不是与潜在目标的业务合并协议的一方。2018年至2020年，Qureshi先生在投资管理公司景顺投资管理公司的私人投资部门景顺 Private Markets担任管理合伙人，并从2015年起担任董事总经理，以及WL Ross & Co. LLC的管理合伙人，该公司是一家专注于投资于存在财务困境且股票被低估的公司的私募股权公司。自2006年以来，该公司一直作为景顺投资管理公司的全资子公司在2012年至2015年期间运营。Qureshi先生是私募股权公司Quinpario Partners LLC的合伙人。2005年至2012年，他在Solutia，Inc.担任高级管理人员（2011年8月起担任新兴市场高级副总裁），并且是领导Solutia从一家破产的初级商品生产商向盈利的特种化学品业务进行重组和转型的管理团队的一部分，直到2012年将其出售给伊士曼化工。2000年至2005年，Qureshi先生曾任职于全球管理咨询公司Arthur D. Little和全球咨询公司Charles River Associates。Qureshi先生于2021年7月至2024年2月期间担任International Seaways（NYSE：INSW）董事会成员，并于2017年至2021年期间担任Diamond S Shipping（NYSE：DSSI）董事会成员（于2019年至2021年期间担任董事长），并于2016年至2017年期间担任Nexeo Solutions（NASDAQ：NXEO）董事会成员。Qureshi先生拥有凯斯西储大学化学工程理学学士学位和微分子科学理学硕士学位，以及西北大学工商管理硕士学位。
Nadim Qureshi director since June 12, 2025, is the managing partner of BPGC Management LP, a global private equity firm foced on transactions with the global indtrials, materials and chemicals sectors, which he co founded in 2020, where he is responsible for all aspects of firm and investment management. Mr. Qureshi has served as a director and officer of special purpose companies as Chairman of the Board, Chief Executive Officer and a director of BPGC Acquisition Corp. (formerly known as Ross Acquisition Corp II) since November 12, 2024 and prior thereto as Head of M&A since its inception in January 2021, as Vice President and Chief Strategy Officer of Quinpario Acquisition Corp. ("Quinpario") from May 13, 2013 until June 30, 2014, and as a Managing Director for WL Ross & Co. LLC, an affiliate of the sponsor of WL Ross Holding Corp., Mr. Qureshi supervised the Biness Combination of WL Ross Holding Corp. with Nexeo Solutions, Inc. and served as a board member of the combined company from 2016 to 2017. See "Prior SPAC Experience." From 2018 to 2020, Mr. Qureshi served as Managing Partner at Invesco Private Markets, a private investing division of Invesco Ltd., an investment management company, and from 2015 served as Managing Director, and as Managing Partner of WL Ross & Co. LLC, a private equity firm foced on investments in financially distressed companies with undervalued stocks. which since 2006 has been operating as a wholly owned subsidiary of Invesco Ltd. From 2012 to 2015, Mr. Qureshi was a Partner at Quinpario Partners LLC, a private equity firm. From 2005 to 2012, he was a senior executive with Solutia, Inc. (as Senior Vice President, Emerging Markets from Augt 2011), and part of the management team that led the restructuring and transformation of Solutia from a bankrupt commodity producer to a profitable specialty chemicals biness until its sale to Eastman Chemical in 2012. From 2000 to 2005, Mr. Qureshi worked at Arthur D. Little, a global management consulting firm, and Charles River Associates, a global consulting firm. Mr. Qureshi also was a member of the Board of Directors of International Seaways (NYSE:INSW) from July 2021 until February 2024 and Diamond S Shipping (NYSE:DSSI) from 2017 to 2021 (as Chairman from 2019 until its merger in 2021), Mr. Qureshi has a Bachelor of Science degree in Chemical Engineering and a Master of Science degree in Micromolecular Science from Case stern Reserve University, as ll as a Master of Biness Administration degree from Northstern University. - Nadim Qureshi是BPGC Management LP的管理合伙人，该公司是一家专注于与全球工业、材料和化学品领域交易的全球私募股权公司，他于2020年与他人共同创立了该公司，负责公司和投资管理的各个方面。Qureshi先生自2021年1月起担任特殊目的收购公司BPGC Acquisition Corp.（原名Ross Acquisition Corp II，或“RAC II”）的并购主管，直至2024年底被任命为首席执行官。2021年3月16日，RAC II完成了34,500，000台的首次公开发行，总收益为345,000，000美元。RAC II的单位（以及单位中包含的A类普通股和认股权证）在纽约证券交易所（“NYSE”）上市，直到2024年4月3日，由于未能在其初始业务合并后的三年内完成初始业务合并而被摘牌。2024年9月16日，RAC将完成初步业务合并的期限延长至2026年3月16日。RAC II尚未完成其初始业务合并，目前不是与潜在目标的业务合并协议的一方。2018年至2020年，Qureshi先生在投资管理公司景顺投资管理公司的私人投资部门景顺 Private Markets担任管理合伙人，并从2015年起担任董事总经理，以及WL Ross & Co. LLC的管理合伙人，该公司是一家专注于投资于存在财务困境且股票被低估的公司的私募股权公司。自2006年以来，该公司一直作为景顺投资管理公司的全资子公司在2012年至2015年期间运营。Qureshi先生是私募股权公司Quinpario Partners LLC的合伙人。2005年至2012年，他在Solutia，Inc.担任高级管理人员（2011年8月起担任新兴市场高级副总裁），并且是领导Solutia从一家破产的初级商品生产商向盈利的特种化学品业务进行重组和转型的管理团队的一部分，直到2012年将其出售给伊士曼化工。2000年至2005年，Qureshi先生曾任职于全球管理咨询公司Arthur D. Little和全球咨询公司Charles River Associates。Qureshi先生于2021年7月至2024年2月期间担任International Seaways（NYSE：INSW）董事会成员，并于2017年至2021年期间担任Diamond S Shipping（NYSE：DSSI）董事会成员（于2019年至2021年期间担任董事长），并于2016年至2017年期间担任Nexeo Solutions（NASDAQ：NXEO）董事会成员。Qureshi先生拥有凯斯西储大学化学工程理学学士学位和微分子科学理学硕士学位，以及西北大学工商管理硕士学位。
- Nadim Qureshi director since June 12, 2025, is the managing partner of BPGC Management LP, a global private equity firm foced on transactions with the global indtrials, materials and chemicals sectors, which he co founded in 2020, where he is responsible for all aspects of firm and investment management. Mr. Qureshi has served as a director and officer of special purpose companies as Chairman of the Board, Chief Executive Officer and a director of BPGC Acquisition Corp. (formerly known as Ross Acquisition Corp II) since November 12, 2024 and prior thereto as Head of M&A since its inception in January 2021, as Vice President and Chief Strategy Officer of Quinpario Acquisition Corp. ("Quinpario") from May 13, 2013 until June 30, 2014, and as a Managing Director for WL Ross & Co. LLC, an affiliate of the sponsor of WL Ross Holding Corp., Mr. Qureshi supervised the Biness Combination of WL Ross Holding Corp. with Nexeo Solutions, Inc. and served as a board member of the combined company from 2016 to 2017. See "Prior SPAC Experience." From 2018 to 2020, Mr. Qureshi served as Managing Partner at Invesco Private Markets, a private investing division of Invesco Ltd., an investment management company, and from 2015 served as Managing Director, and as Managing Partner of WL Ross & Co. LLC, a private equity firm foced on investments in financially distressed companies with undervalued stocks. which since 2006 has been operating as a wholly owned subsidiary of Invesco Ltd. From 2012 to 2015, Mr. Qureshi was a Partner at Quinpario Partners LLC, a private equity firm. From 2005 to 2012, he was a senior executive with Solutia, Inc. (as Senior Vice President, Emerging Markets from Augt 2011), and part of the management team that led the restructuring and transformation of Solutia from a bankrupt commodity producer to a profitable specialty chemicals biness until its sale to Eastman Chemical in 2012. From 2000 to 2005, Mr. Qureshi worked at Arthur D. Little, a global management consulting firm, and Charles River Associates, a global consulting firm. Mr. Qureshi also was a member of the Board of Directors of International Seaways (NYSE:INSW) from July 2021 until February 2024 and Diamond S Shipping (NYSE:DSSI) from 2017 to 2021 (as Chairman from 2019 until its merger in 2021), Mr. Qureshi has a Bachelor of Science degree in Chemical Engineering and a Master of Science degree in Micromolecular Science from Case stern Reserve University, as ll as a Master of Biness Administration degree from Northstern University.
- Dario Dino Ferrari
-
Dario Dino 法拉利，自2000年6月起担任法拉利 Express Inc.（“FEI”）总裁。作为法拉利 Express的总裁和股东，他成功地拓宽了公司的活动范围，特别是在安全和物流领域，将业务延伸到加拿大、巴西和墨西哥。他还担任过总部位于纽约的物流公司法拉利 Logistics，Inc.的首席执行官，直到2016年1月该公司与FEI合并。法拉利先生获得了米兰天主教大学的法学学位。
Dario Dino Ferrari director since June 12, 2025, has been the President of Ferrari Express Inc. ("FEI") since June 2000. As the President and shareholder of Ferrari Express, he successfully broadened the company's activities, particularly in the fields of security and logistics, extending operations into Canada, Brazil, and Mexico. He also served as the CEO of Ferrari Logistics, Inc., a New York based logistics company, until it was merged with FEI in January 2016. Mr. Ferrari received a Law Degree from the Catholic University of Milan. - Dario Dino 法拉利，自2000年6月起担任法拉利 Express Inc.（“FEI”）总裁。作为法拉利 Express的总裁和股东，他成功地拓宽了公司的活动范围，特别是在安全和物流领域，将业务延伸到加拿大、巴西和墨西哥。他还担任过总部位于纽约的物流公司法拉利 Logistics，Inc.的首席执行官，直到2016年1月该公司与FEI合并。法拉利先生获得了米兰天主教大学的法学学位。
- Dario Dino Ferrari director since June 12, 2025, has been the President of Ferrari Express Inc. ("FEI") since June 2000. As the President and shareholder of Ferrari Express, he successfully broadened the company's activities, particularly in the fields of security and logistics, extending operations into Canada, Brazil, and Mexico. He also served as the CEO of Ferrari Logistics, Inc., a New York based logistics company, until it was merged with FEI in January 2016. Mr. Ferrari received a Law Degree from the Catholic University of Milan.
高管简历
中英对照 | 中文 | 英文- Ketan Seth
Ketan Seth，自2025年2月10日起担任公司董事，自2025年2月10日起担任首席执行官，在科技领域以及数据中心领域拥有20年的交易经验。自2022年10月以来，Seth先生一直担任Vezbi的首席执行官，Vezbi是美国首家专注于为美国以及拉丁美洲的B2B客户提供远程医疗以及小额支付和汇款系统等医疗保健服务的超级应用程序。此外，自2020年8月以来，Seth先生一直担任AT Health Inc.（前身为Innovative Health Consulting LLC）的首席执行官，自2011年1月以来，Seth先生一直担任Alpha Trading LLC的管理合伙人，该公司是一家总部位于美国的私人投资控股公司，专注于金融科技和医疗保健。2005年至2012年，Seth先生担任创新物流解决方案的首席执行官。2000年至2004年，Seth先生在德意志银行投资银行部门工作，协助处理交易流程和私募发行。1998年至2000年，Seth先生在德勤咨询公司担任业务战略顾问。塞思先生在密歇根大学获得经济学学士学位，在纽约大学斯特恩商学院获得MBA学位，在那里他专注于金融、创业和战略。
Ketan Seth a director since February 10, 2025 and Chief Executive Officer since February 10, 2025, has 20 years of deal making experience in the tech sector as ll as in the data centers space. Since October 2022, Mr. Seth has been the Chief Executive Officer of Vezbi, the first American Super App focused on healthcare services such as telemedicine and small payment and remittance systems for B2B clients both in the as ll as LatAm. In addition, since August 2020, Mr. Seth has been Chief Executive Officer of AT Health Inc. (formerly Innovative Health Consulting LLC) and since January 2011, Mr. Seth has been managing partner of Alpha Trading LLC, a based private investment holding company focused on fintech and healthcare. From 2005 to 2012, Mr. Seth was Chief Executive Officer of Innovative Logistics Solutions. From 2000 to 2004, Mr. Seth worked in the Deutsche Bank Investment Banking division, assisting on deal flow and private placements. From 1998 to 2000, Mr. Seth served as a Biness Strategy Consultant at Deloitte Consulting. Mr. Seth earned a BA in Economics from University of Michigan and an MBA from the Stern School of Biness at NYU, where he focused in Finance, Entrepreneurship and Strategy.- Ketan Seth，自2025年2月10日起担任公司董事，自2025年2月10日起担任首席执行官，在科技领域以及数据中心领域拥有20年的交易经验。自2022年10月以来，Seth先生一直担任Vezbi的首席执行官，Vezbi是美国首家专注于为美国以及拉丁美洲的B2B客户提供远程医疗以及小额支付和汇款系统等医疗保健服务的超级应用程序。此外，自2020年8月以来，Seth先生一直担任AT Health Inc.（前身为Innovative Health Consulting LLC）的首席执行官，自2011年1月以来，Seth先生一直担任Alpha Trading LLC的管理合伙人，该公司是一家总部位于美国的私人投资控股公司，专注于金融科技和医疗保健。2005年至2012年，Seth先生担任创新物流解决方案的首席执行官。2000年至2004年，Seth先生在德意志银行投资银行部门工作，协助处理交易流程和私募发行。1998年至2000年，Seth先生在德勤咨询公司担任业务战略顾问。塞思先生在密歇根大学获得经济学学士学位，在纽约大学斯特恩商学院获得MBA学位，在那里他专注于金融、创业和战略。
- Ketan Seth a director since February 10, 2025 and Chief Executive Officer since February 10, 2025, has 20 years of deal making experience in the tech sector as ll as in the data centers space. Since October 2022, Mr. Seth has been the Chief Executive Officer of Vezbi, the first American Super App focused on healthcare services such as telemedicine and small payment and remittance systems for B2B clients both in the as ll as LatAm. In addition, since August 2020, Mr. Seth has been Chief Executive Officer of AT Health Inc. (formerly Innovative Health Consulting LLC) and since January 2011, Mr. Seth has been managing partner of Alpha Trading LLC, a based private investment holding company focused on fintech and healthcare. From 2005 to 2012, Mr. Seth was Chief Executive Officer of Innovative Logistics Solutions. From 2000 to 2004, Mr. Seth worked in the Deutsche Bank Investment Banking division, assisting on deal flow and private placements. From 1998 to 2000, Mr. Seth served as a Biness Strategy Consultant at Deloitte Consulting. Mr. Seth earned a BA in Economics from University of Michigan and an MBA from the Stern School of Biness at NYU, where he focused in Finance, Entrepreneurship and Strategy.
- David Bauer
David Bauer，自2025年2月25日起担任首席财务官并担任董事，在2015年至2025年1月期间，他担任数字媒体物业和管理公司Matters Media（现为Engrost Inc.）的首席执行官兼董事，在那里他领导了该控股公司的所有运营和并购活动，包括金融业务。2012年至2015年，Bauer先生担任Zenia集团金融服务领域的运营、并购咨询主管。2007年至2010年，Bauer先生受雇于高盛 Sachs，担任不良贷款和票面贷款的管理、交易和服务方面的金融分析师，并且是合成银行贷款团队的负责人。
David Bauer Chief Financial Officer since February 25, 2025 and a director since June 12, 2025, served as CEO and a director of Matters Media (now Engrost Inc.), a digital media properties and management firm, from 2015 to January 2025, where he led all operations and M&A activity for the holding company, including financial operations. From 2012 to 2015, Mr. Bauer was head of operations, M&A Advisory in the financial services sector for Zenia Group. From 2007 to 2010, Mr. Bauer was employed by Goldman Sachs as a Financial Analyst in management, trading and servicing of distressed and par loans and was leader of the synthetic bank loans team.- David Bauer，自2025年2月25日起担任首席财务官并担任董事，在2015年至2025年1月期间，他担任数字媒体物业和管理公司Matters Media（现为Engrost Inc.）的首席执行官兼董事，在那里他领导了该控股公司的所有运营和并购活动，包括金融业务。2012年至2015年，Bauer先生担任Zenia集团金融服务领域的运营、并购咨询主管。2007年至2010年，Bauer先生受雇于高盛 Sachs，担任不良贷款和票面贷款的管理、交易和服务方面的金融分析师，并且是合成银行贷款团队的负责人。
- David Bauer Chief Financial Officer since February 25, 2025 and a director since June 12, 2025, served as CEO and a director of Matters Media (now Engrost Inc.), a digital media properties and management firm, from 2015 to January 2025, where he led all operations and M&A activity for the holding company, including financial operations. From 2012 to 2015, Mr. Bauer was head of operations, M&A Advisory in the financial services sector for Zenia Group. From 2007 to 2010, Mr. Bauer was employed by Goldman Sachs as a Financial Analyst in management, trading and servicing of distressed and par loans and was leader of the synthetic bank loans team.